GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Curis Inc (NAS:CRIS) » Definitions » Cyclically Adjusted Price-to-FCF

Curis (CRIS) Cyclically Adjusted Price-to-FCF : (As of Apr. 30, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Curis Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Curis Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Curis's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curis Cyclically Adjusted Price-to-FCF Chart

Curis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Curis Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Curis's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Curis's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Curis's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Curis's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Curis's Cyclically Adjusted Price-to-FCF falls into.



Curis Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Curis's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Curis's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-1.763/129.4194*129.4194
=-1.763

Current CPI (Dec. 2023) = 129.4194.

Curis Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -6.177 99.695 -8.019
201406 -5.500 100.560 -7.078
201409 -2.424 100.428 -3.124
201412 -5.456 99.070 -7.127
201503 -7.205 99.621 -9.360
201506 -5.285 100.684 -6.793
201509 -3.517 100.392 -4.534
201512 -8.447 99.792 -10.955
201603 -6.198 100.470 -7.984
201606 -8.586 101.688 -10.927
201609 -5.750 101.861 -7.306
201612 -6.710 101.863 -8.525
201703 -10.703 102.862 -13.466
201706 -6.465 103.349 -8.096
201709 -11.264 104.136 -13.999
201712 -4.596 104.011 -5.719
201803 -6.074 105.290 -7.466
201806 -4.187 106.317 -5.097
201809 -4.964 106.507 -6.032
201812 -2.983 105.998 -3.642
201903 -4.362 107.251 -5.264
201906 -4.022 108.070 -4.817
201909 -4.039 108.329 -4.825
201912 -3.373 108.420 -4.026
202003 -5.373 108.902 -6.385
202006 -2.727 108.767 -3.245
202009 -2.212 109.815 -2.607
202012 -1.737 109.897 -2.046
202103 -2.881 111.754 -3.336
202106 -1.455 114.631 -1.643
202109 -2.098 115.734 -2.346
202112 -1.784 117.630 -1.963
202203 -3.672 121.301 -3.918
202206 -2.724 125.017 -2.820
202209 -2.809 125.227 -2.903
202212 -2.544 125.222 -2.629
202303 -2.525 127.348 -2.566
202306 -1.628 128.729 -1.637
202309 -1.430 129.860 -1.425
202312 -1.763 129.419 -1.763

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Curis  (NAS:CRIS) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Curis Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Curis's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Curis (CRIS) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Curis Inc (NAS:CRIS) » Definitions » Cyclically Adjusted Price-to-FCF
Traded in Other Exchanges
Address
128 Spring Street, Building C - Suite 500, Lexington, MA, USA, 02421
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
Executives
Jonathan B. Zung officer: CDO C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Anne Elizabeth Borgman director 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
John Hohneker director C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE 4TH FLOOR, CAMBRIDGE MA 02139
Marc Rubin director C/O TITAN PHARMACEUTICALS, INC., 400 OYSTER POINT BLVD., STE 505, SAN FRANCISCO CA 94080
Kenneth I Kaitin director C/O TUFTS CNTR FOR THE STUDY OF DRUG DEV, 75 KNEELAND ST, SUITE 1100, BOSTON MA 02111
Martyn D Greenacre director 41 MOORES ROAD, FRAZER PA 19355
Robert Martell officer: Head of Research & Development 4 MAGUIRE ROAD, LEXINGTON MA 02421
Diantha Duvall officer: CFO C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
James E Dentzer director, officer: President & CEO C/O AMICUS THERAPEUTICS, INC., 6 CEDAR BROOK DRIVE, CRANBURY NJ 08512
William Steinkrauss officer: VP, Finance & Treasurer, other: Principal Accounting Officer C/O CURIS, INC.,, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Lori Anne Kunkel director C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Fattaey Ali Ph.d. officer: President & COO C/O CURIS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
James R Mcnab director C/O CURIS, INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Aurigene Discovery Technologies Ltd 10 percent owner 39-40 KIADB INDUSTRIAL AREA, PHASE II, ELECTRONIC CITY HOSUR ROAD, BANGALORE (KARNATAKA) K7 560100
David Tuck officer: Sr. Vice-President C/O CURIS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421